Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 studyLihua E. Budde, Nancy L. Bartlett, Antonia Kwan et al.|The Lancet Oncology|2022Cited by 429
Late Morbidity and Mortality in Patients with Hodgkin's Lymphoma Treated During AdulthoodMatthew J. Matasar, David J. Straus|JNCI Journal of the National Cancer Institute|2015Cited by 45
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 studyMax S. Topp, Jennifer L. Crombie, Matthew J. Matasar et al.|Blood|2024Cited by 28
Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell LymphomaAlex F. Herrera, Matthew J. Matasar, Lu Chen et al.|Blood|2022Cited by 18
Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLLAdam S. Kittai, Jennifer A. Woyach, Ying Huang et al.|Blood Cancer Journal|2025Cited by 12